Clinical efficacy of Daikenchuto (DKT: TJ-100) for gastrointestinal symptoms in patients with a history of colon and rectosigmoid cancer surgery: a randomized crossover study

• Published in: Surgery today (Tokyo, Japan) Vol. 53; no. 8; pp. 873 - 881
• Main Authors: Sada, Haruki, Sawada, Hiroyuki, Tokunaga, Masakazu, Shimomura, Manabu, Egi, Hiroyuki, Hattori, Minoru, Ohge, Hiroki, Ohdan, Hideki, Hinoi, Takao
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.08.2023
• Subjects: Medicine; Medicine & Public Health; Original Article; Surgery; Surgical Oncology; Daikenchuto; Colorectal cancer; Gastrointestinal syndrome
• ISSN: 0941-1291; 1436-2813
• DOI: 10.1007/s00595-022-02640-2

Purpose This randomized crossover trial investigated the effects of Daikenchuto (DKT: TJ-100) on gastrointestinal symptoms of patients after colon and rectosigmoid cancer surgery. Methods Among patients who had completed surgery for colon cancer, including rectosigmoid cancer, over 6 months ago, 20 who complained of gastrointestinal symptoms were enrolled. Subjects were randomly assigned to two sequences: sequences: A and B . In period 1, sequence A subjects were orally administered DKT, whereas sequence B subjects were untreated for 28 days. After a 5-day interval, in period 2, sequences A and B were reversed. Quality-of-life markers (GSRS and VAS), the Sitzmark transit study, the orocecal transit time (lactulose hydrogen breath test) and Gas volume score were evaluated before and after each period with findings compared between the presence of absence of DKT administration. Results Between sequences, there were no significant differences in clinicopathological characters or any evaluations before randomization. There was no carryover effect in this crossover trial. The administration of DKT significantly ameliorated the GSRS in total, indigestion, and diarrhea, although the planned number of subjects for inclusion in this trial was not reached. Conclusions DKT may ameliorate subjective symptoms for postoperative patients who complain of gastrointestinal symptoms.